|
|
Article: Chromos Enters Licensing Deal With CAT For Antibody Work.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
National Editor
Chromos Molecular Systems Inc. entered its first licensing deal focused on its artificial chromosome expression system, known as ACE, signing up with Cambridge Antibody Technology Group plc, which will use the system to manufacture antibodies and biologics.
CAT, of Cambridge, UK, will use the platform - which it said fits well with its phage display technology - to generate cell lines expressing monoclonal antibodies. The company retains the right to manufacture and sell therapeutic products that emerge from the Chromos deal.
Helen Zeitler, director of investor relations and communications for Burnaby, British Columbia-based ...